Market Overview

2018 Veeva R&D Summit to Showcase Advances for Speeding Product Development


More than 100 life sciences experts will share best practices to
unify processes in clinical, regulatory, and quality

(NYSE:VEEV) will host the 2018
Veeva R&D Summit
from September 16-18 in Philadelphia. The event
will bring together more than 1,300 life sciences professionals and
experts showcasing the latest advancements for speeding product
development in the industry.

The conference opens with Nick Leschly, chief bluebird at bluebird bio,
discussing the potential of breakthrough innovations in treating genetic
and rare diseases. Mr. Leschly will sit down with Matt Wallach,
president and co-founder of Veeva, in a fireside chat on "Bringing Gene
Therapy-Powered Hope to Reality."

More than 100 leading pharmaceutical, biotech, and medical device
professionals will share in-depth best practices for streamlining
product development processes in clinical, regulatory, and quality. This
year's event features keynotes on optimizing trial performance,
reinventing clinical data management, modernizing quality management,
and regulatory transformation:

  • Janssen Pharmaceuticals, Pharmaceutical Product Development LLC
    (PPD), and IACT Health
    identify opportunities to improve clinical
    information exchange for better trial collaboration and execution
    across sponsors, CROs, and sites.
  • Cara Therapeutics explains how they improved clinical data
    management with a modern EDC solution to speed study database build
    and design.
  • Bristol-Myers Squibb share their vision to modernize quality
    management globally and transform the change management process with a
    strategic, enterprise-wide initiative.
  • Eli Lilly and Company discuss their innovative approach to RIM
    transformation and implementing an end-to-end process for
    post-approval changes on a single RIM platform.

Veeva founder and CEO, Peter Gassner, will deliver a keynote on how
Veeva Vault is enabling the industry to transform product development
processes in clinical, regulatory, quality, and soon safety. He will
also unveil Veeva's vision to help sponsors, CROs, and sites seamlessly
collaborate during clinical trials. Jen Goldsmith, senior vice president
of Veeva Vault, and Avril England, general manager of Veeva Vault, will
showcase how Veeva
Development Cloud
manages global end-to-end processes such as
variation management and change control across research and development.

More than 60 sessions and workshops will feature speakers from AbbVie,
Agios Pharmaceuticals, Alkermes PLC, Allakos, Atlantic Research Group,
BioEnterprise, Clintec, Gilead Sciences, Inc., GlaxoSmithKline, ICON
plc, Incyte Corporation, Integra LifeSciences, Intersect ENT, Ionis
Pharmaceuticals, Inc., Melinta Therapeutics Inc., Ora, Inc., Radius
Health, Regeneron Pharmaceuticals Inc., Replimune Group Inc., Seattle
Genetics, Inc., Syneos Health, Sysmex Corporation, TESARO, Inc.,
Ultragenyx Pharmaceutical Inc., and Upsher-Smith Laboratories LLC, among

2018 Veeva R&D Summit is sponsored by Accenture, AG Mednet, Amazon Web
Services, C3i Solutions, CGI, Cognizant, Comprehend Systems, Inc.,
Deloitte, EY, FME, Ideagen Plc, LPW Training Services, Mavens, NNIT,
Qlik, SDL, Tata Consultancy Services, Trifecta, UL PURE Learning, and
Valiance Partners.

In other news today, Veeva announced the availability of Veeva
Vault Submissions Publishing
, as well as continued momentum with
customers adopting Veeva
Vault CTMS
. Read the Vault
Submissions Publishing news
and Vault
CTMS news
to learn more.

Veeva R&D Summit is a complimentary event for Veeva customers and
invited guests. Learn more, register, and view the full agenda at

Additional Information

Connect with Veeva on LinkedIn:

Follow @veevasystems on Twitter:

Like Veeva on Facebook:

About Veeva Systems

Veeva Systems Inc. is a leader in cloud-based software for the global
life sciences industry. Committed to innovation, product excellence, and
customer success, Veeva has more than 650 customers, ranging from the
world's largest pharmaceutical companies to emerging biotechs. Veeva is
headquartered in the San Francisco Bay Area, with offices throughout
North America, Europe, Asia, and Latin America. For more information,

Forward-looking Statements

This release contains forward-looking statements, including the market
demand for and acceptance of Veeva's products and services, the results
from use of Veeva's products and services, and general business
conditions, particularly in the life sciences industry. Any
forward-looking statements contained in this press release are based
upon Veeva's historical performance and its current plans, estimates,
and expectations, and are not a representation that such plans,
estimates, or expectations will be achieved. These forward-looking
statements represent Veeva's expectations as of the date of this press
announcement. Subsequent events may cause these expectations to change,
and Veeva disclaims any obligation to update the forward-looking
statements in the future. These forward-looking statements are subject
to known and unknown risks and uncertainties that may cause actual
results to differ materially. Additional risks and uncertainties that
could affect Veeva's financial results are included under the captions,
"Risk Factors" and "Management's Discussion and Analysis of Financial
Condition and Results of Operations," in the company's filing on Form
10-Q for the period ended April 30, 2018. This is available on the
company's website at
under the Investors section and on the SEC's website at
Further information on potential risks that could affect actual results
will be included in other filings Veeva makes with the SEC from time to

View Comments and Join the Discussion!